• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Outset Medical Inc.

    11/12/24 10:32:13 AM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $OM alert in real time by email
    SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.5 OUTSET MEDICAL INC COMMON STOCK Cusip #690145107 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #690145107 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 4,766,119 Item 6: 0 Item 7: 4,773,776 Item 8: 0 Item 9: 4,773,776 Item 11: 9.164% Item 12: HC Cusip #690145107 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 4,773,776 Item 8: 0 Item 9: 4,773,776 Item 11: 9.164% Item 12: IN Item 1(a). Name of Issuer: OUTSET MEDICAL INC Item 1(b). Address of Issuer's Principal Executive Offices: 3052 Orchard Drive San Jose, CA 95134 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 690145107 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 4,773,776 (b) Percent of Class: 9.164% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 4,773,776 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of OUTSET MEDICAL INC. The interest of Select Medical Technology and Devices Portfolio, in the COMMON STOCK of OUTSET MEDICAL INC, amounted to 3,300,000 shares or 6.335% of the total outstanding COMMON STOCK at September 30, 2024. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. November 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Management & Research Company LLC * IA Fidelity Management Trust Company BK Strategic Advisers LLC IA * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on November 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of OUTSET MEDICAL INC at September 30, 2024. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.
    Get the next $OM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OM

    DatePrice TargetRatingAnalyst
    8/8/2024$6.00 → $3.00Outperform → Sector Perform
    RBC Capital Mkts
    6/21/2024$5.00 → $6.00Sector Perform → Outperform
    RBC Capital Mkts
    4/8/2024$6.00Buy
    BTIG Research
    4/5/2024$6.00Neutral → Buy
    CL King
    1/12/2024$14.00 → $6.00Outperform → Sector Perform
    RBC Capital Mkts
    10/13/2023$32.00 → $3.00Buy → Underperform
    BofA Securities
    8/17/2023Neutral
    CL King
    11/11/2022$23.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $OM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Outset Medical to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

      SAN JOSE, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that management will present at the Goldman Sachs 46th annual Healthcare conference on Wednesday, June 11, 2025, at 11:20 a.m. Eastern time. A live and archived webcast of the presentation will be available on the "Investors" section of the Outset website at https://investors.outsetmedical.com/. About Outset Medical, Inc.Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo® Hem

      6/5/25 9:05:00 AM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Outset Medical Appoints Renee Gaeta as Chief Financial Officer

      SAN JOSE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced the appointment of Renee Gaeta as Chief Financial Officer (CFO), effective immediately. In addition to leading Finance, Ms. Gaeta will have responsibility for Outset's Information Technology and Human Resources organizations. She succeeds Nabeel Ahmed who is leaving the company to pursue other opportunities. "Renee brings deep financial and leadership experience to Outset with a proven track record from her roles at publicly traded medical-device growth companie

      6/3/25 4:30:00 PM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Outset Medical Appoints Industry Veteran Kevin O'Boyle to its Board of Directors

      SAN JOSE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced the appointment of healthcare industry veteran Kevin O'Boyle to its Board of Directors and as chair of its Audit Committee. With Mr. O'Boyle's appointment, the company also announced that Dale E. Jones has stepped down from the Board. "Kevin's over 20 years of healthcare leadership experience span roles as CFO of several publicly traded companies and as a board director of 6 public medical device companies," said Leslie Trigg, Chair and CEO. "His expertise in c

      5/14/25 9:00:00 AM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $OM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP Operations and R&D Nash Marc was granted 29,676 shares, increasing direct ownership by 220% to 43,141 units (SEC Form 4)

      4 - Outset Medical, Inc. (0001484612) (Issuer)

      6/11/25 5:34:53 PM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • General Counsel Brottem John L. was granted 35,993 shares, increasing direct ownership by 319% to 47,266 units (SEC Form 4)

      4 - Outset Medical, Inc. (0001484612) (Issuer)

      6/11/25 5:33:48 PM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chair and CEO Trigg Leslie was granted 65,103 shares, increasing direct ownership by 112% to 123,232 units (SEC Form 4)

      4 - Outset Medical, Inc. (0001484612) (Issuer)

      6/11/25 5:32:16 PM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $OM
    Leadership Updates

    Live Leadership Updates

    See more
    • Outset Medical Appoints Industry Veteran Kevin O'Boyle to its Board of Directors

      SAN JOSE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced the appointment of healthcare industry veteran Kevin O'Boyle to its Board of Directors and as chair of its Audit Committee. With Mr. O'Boyle's appointment, the company also announced that Dale E. Jones has stepped down from the Board. "Kevin's over 20 years of healthcare leadership experience span roles as CFO of several publicly traded companies and as a board director of 6 public medical device companies," said Leslie Trigg, Chair and CEO. "His expertise in c

      5/14/25 9:00:00 AM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Masimo Announces Leadership Transition

      Katie Szyman Appointed Chief Executive Officer and to Board of Directors Interim CEO Michelle Brennan Named Chairman of Masimo's Board Today the Board of Directors (the "Board") of Masimo (NASDAQ:MASI), a leading global medical innovator, announced that Katie Szyman has been appointed the next Chief Executive Officer ("CEO") of the Company. Interim CEO Michelle Brennan has been appointed Chairman of Masimo's Board and Lead Independent Director Quentin Koffey has been appointed Vice Chairman. All of these changes are effective as of February 12, 2025. Ms. Szyman is currently worldwide president of Advanced Patient Monitoring at BD (Becton, Dickinson and Company). Previously, Ms. Szyman

      1/21/25 4:00:00 PM ET
      $MASI
      $NARI
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medical/Dental Instruments
    • Outset Medical Names Business Leader Dale E. Jones to Board of Directors

      Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company reducing the cost and complexity of dialysis, today announced the appointment of Dale E. Jones to its Board of Directors. "Dale brings more than 30 years of experience in building diverse and dynamic teams to Outset at a time of exceptional growth for our team," said Chair and CEO Leslie Trigg. "He leads with purpose and deeply understands the role values and culture play in building high-performance organizations, critical traits as we focus on transforming dialysis." Mr. Jones is a Senior Advisor at Diversified Search Group, and previously served as its CEO for more than eight years. He began his career in banking

      4/25/22 4:00:00 PM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $OM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Outset Medical Inc.

      SC 13G/A - Outset Medical, Inc. (0001484612) (Subject)

      11/12/24 4:53:46 PM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Outset Medical Inc.

      SC 13G/A - Outset Medical, Inc. (0001484612) (Subject)

      11/12/24 4:26:01 PM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Outset Medical Inc.

      SC 13G/A - Outset Medical, Inc. (0001484612) (Subject)

      11/12/24 10:32:13 AM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $OM
    Financials

    Live finance-specific insights

    See more
    • Outset Medical First-Quarter Results Demonstrate Strong Growth in Console and Recurring Revenue as Gross Margin Expanded and Cash Use Declined

      SAN JOSE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the first quarter ended March 31, 2025. First Quarter and Recent Highlights Net revenue of $29.8 million grew 6% from the prior-year period.Tablo console revenue grew 23% from the fourth quarter.Recurring revenue consisting of Tablo consumables and services grew 20% over the prior-year period to $22.7 million. Outset shipped its 3 millionth Tablo treatment during the quarter, adding 1 million treatments over a period of approximately 12 months.Gross ma

      5/7/25 4:02:00 PM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Outset Medical to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025

      SAN JOSE, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the first quarter 2025 after the close of trading on Wednesday, May 7, 2025. On the same day, at 2:00 p.m. Pacific time (5:00 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Nabeel Ahmed, Chief Financial Officer, will host a conference call to discuss financial and operating results. Conference Call DetailsThe conference call will begin at 2:00 p.m. Pacific time (5:00 p.m. Eastern time) on

      4/16/25 4:32:00 PM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Outset Medical Reports Fourth Quarter and Full Year 2024 Financial Results

      SAN JOSE, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter, Year-End Highlights Net revenue of $29.5 million in the fourth quarter and $113.7 million in 2024 were both ahead of the company's prior guidance and preannouncement in January.Gross margin of 36.5% (37.7% on a non-GAAP basis) in the fourth quarter increased 220 basis points sequentially from the third quarter and 11 percentage points from the fourth quarter of 2023. Gross margi

      2/19/25 4:03:00 PM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $OM
    SEC Filings

    See more
    • SEC Form S-8 filed by Outset Medical Inc.

      S-8 - Outset Medical, Inc. (0001484612) (Filer)

      6/5/25 4:00:45 PM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Outset Medical Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Outset Medical, Inc. (0001484612) (Filer)

      6/3/25 4:35:27 PM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SD filed by Outset Medical Inc.

      SD - Outset Medical, Inc. (0001484612) (Filer)

      5/29/25 4:05:14 PM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $OM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Outset Medical downgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts downgraded Outset Medical from Outperform to Sector Perform and set a new price target of $3.00 from $6.00 previously

      8/8/24 6:47:35 AM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Outset Medical upgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts upgraded Outset Medical from Sector Perform to Outperform and set a new price target of $6.00 from $5.00 previously

      6/21/24 6:53:06 AM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BTIG Research initiated coverage on Outset Medical with a new price target

      BTIG Research initiated coverage of Outset Medical with a rating of Buy and set a new price target of $6.00

      4/8/24 7:26:20 AM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care